Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Exenatide on Disease Progression in Early Parkinson’s Disease – Open-Label Extension
2024-520069-30-00Phase 2Completed
- Sponsor
- Region Stockholm
- Start
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exenatide in Parkinson's disease (PD), sponsored by Region Stockholm. Primary endpoint: FDG-PET network analysis at 21 months. Started Dec 2024; status: completed.
02
Drugs
exenatide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-520069-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520069-30-00.